Metamizol Ababor (Metamizole Magnesium)

The drug blocks cyclooxygenase enzymes, reducing the synthesis of prostaglandins that mediate pain, fever, and inflammation. In addition, it acts centrally to diminish pain perception and exerts a direct spasmolytic effect on smooth muscle, providing relief from visceral cramps.

The appropriate dose is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Dosage regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for Metamizole Magnesium in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metamizole Magnesium belongs to the pyrazolone class, offering analgesic, antipyretic and spasmolytic effects, whereas ibuprofen is a non‑steroidal anti‑inflammatory drug (NSAID) primarily targeting inflammation and pain. Metamizole may be chosen when stronger analgesia or spasm relief is needed, but it carries a distinct risk profile, including rare blood‑cell disorders.

The product should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Ensure the container is tightly closed to maintain stability and prevent degradation.

Metamizol Ababor is intended for oral administration. The tablets or oral formulation should be swallowed whole with an adequate amount of water, unless otherwise directed by a healthcare professional.

The most critical adverse events include agranulocytosis, which can lead to severe infections, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and anaphylaxis. Patients should be monitored for signs of infection, rash, or allergic reactions, and therapy should be discontinued immediately if these occur.

Metamizol Ababor is contraindicated in individuals with known hypersensitivity to Metamizole Magnesium or other pyrazolones, patients with existing severe bone‑marrow suppression, and those who have experienced agranulocytosis with prior use. Caution is also advised for patients with severe hepatic or renal impairment.